Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Agency initiates safety label change and notifies physicians of possible link
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Subscribe To Our Newsletter & Stay Updated
